Vy9/V62 cells represent a fraction ofhuman y/6 cells that is expanded after birth in the periphery, carries markers of activated cells, and becomes a major population in peripheral blood. We found that these cells do not comprise a single population but actually represent two nested sets, the smaller of which, specific for M}~obacterium tuberculosis-pulsed antigen-presenting cells (APC), is contained in a larger set specific for an antigen found on the Molt-4 lymphoma. The larger set, representing 40-80% of all blood y/6 cells, is comprised of cells bearing the Vy9/Cy1 chain . Cells in the smaller, included set have an additional requirement for V62 (and probably for certain permissive junctional regions, since a very small percentage of Vy9/Vb2 cells do not react against mycobacteria-pulsed APC). Optimal stimulation by mycobacteria is dependent on the presence ofAPC, and is not restricted by classical major histocompatibility complex molecules. Some ofthe Vy9/V62 mycobacteria-specific clones are also stimulated by APC pulsed with different bacteria, such as Listeria monocytogenes and Escherichia coli, indicating that the population includes several different patterns of reactivity. These data establish a relationship in humans between specificity and V7/V6 gene usage, and offer an explanation for the peripheral expansion of these y/6 cells.
I
n peripheral blood of normal human donors, 50-70% of y/6 cells carry a TCR using a single set of V genes, namely Vy9 and V62, and a single y constant region, the disulphidelinked Cy1 (1-4). We had previously shown that such cells constitute only a minor fraction ofy/6 cells in the postnatal thymus (4) and suggested, therefore, that the overrepresentation of the single V gene pair was not due to a chemical pairing advantage but rather to selective expansion in the periphery. Suggestive evidence has recently come from Parker et al. (5) , who recently showed that Vy9/V62 cells express CD45RO, a putative marker of activated cells (6) , and that with age, their number increases in the blood, but not in the thymus .
There are two possibilities to explain the selective expansion of Vy9/V62 cells . The first is that these cells are expanded by stimulation with a large number of antigenic peptides in association with monomorphic restriction molecules, in accordance with the model proposed by Davis and Bjorkman (7) , in which the TCRVencoded regions, corresponding to 1311 CDR1 and CDR2, preferentially interact with restriction molecules, while the D, J, and N regions, corresponding to CDR3, contact the antigenic peptide. In support of this view are the rare y/6 cells that see CD1, TL, or Qa, which are nonpolymorphic class I-like molecules (8) (9) (10) (11) .
The second possibility is that the Vy9/V62 cells may be expanded by a limited but powerful set ofligands. These could be oftwo sorts: an environmentally recurring antigen to which the Vy9/V62 pair has a particular affinity, or a "superantigen" of the type known to bind to particular Vs regardless ofthe specificities encoded by the V(D) J junctional sequences, such as some bacterial enterotoxins and the cellular antigen Mls (12, 13) .
To discriminate between the various possibilities, we analyzed the specificities expressed by a large panel of Vy9/V62 cells from adult peripheral blood. Here, we show that the selective expansion is not due to recognition of a common restriction element but rather by the recognition of two powerful ligands. The first is an antigen expressedby the tumor The Journal of Experimental Medicine " Volume 173 June 1991 1311-1322 1 Abbreviations used in this paper. MT, Mycobacterium tuberculosis; PPD, purified protein derivative; SEA, staphylococcal enterotoxin A.
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Antigen Specificities of Vy9/VS2 Cells Total RNA was extracted from 5 x 106 cells as described (4). Single-stranded cDNA was synthesized from 1-5 jig total RNA using an oligo(dT) primer and MMLV reverse transcriptase. 1/20 of each cDNA sample was amplified using the following primers: Vy9, 5'-TCATACAGTTCCTGGTGTCC-3' (173 bases upstream to the Vy9 3' end) ; Cy, 5'-GTGTTTGTGAGCTGCAGCAGT3' (28 bases downstream to the 5' end of the C-III axon, sharing an identical sequence with Cyl and the three major Cy2 alleles) ; VS2, 5'-AGGAAGACCCAAGGTAACACAA3' (173 bases upstream to the VS2 3' end) ; CS, 5'-CTTCACCAGACAAGCGACAT3' (71 bases from the 5' end of the C-I axon); Jyl, 5'-CTTGGAAATGT TGTATTCTTCC-3'; Jb3, 5'-AAGATCAACTCACGGGGCTC-3. The latter two primers were used for genomic DNA samples only. The amplification of the VS expressed in clone F, was obtained by means of the "anchored" PCR, as recently described by Loh et al . (24) . The amplifications were done for 40 cycles (94°C, 1 min; 55°C, 1.5 min; and 72°C, 1.5 min) with 25 pmol of each primer in 50 /Al reactions. PCR products were purified from low melting agarose gel, and one-third of the final volume was used directly for sequencing . Dideoxynucleotide termination sequencing reactions were done with a modified T7 DNA polymerase (Sequenase 2.0 ; United States Biochemical Corp., Cleveland, OH) . The primers used for sequencing were either "internal" VS2, JP, Jbl primers (VS2, 5'-AAGATACTTGCACCATCAGAG-3; JP, 5'-AAGCTTTGTTCCGGGACCAA3; Jb1, 5'-ACTTGGTTCC-ACAGTCACAC-3'), or the same Vy9 and VS2 primers used in the amplifications ; in some cases both strands were sequenced. [3] [4] [5] ,ul of the DNA template was mixed with 5 pmol of primer, 2 /Al of 5 x polymerase buffer, 1 jul DMSO, and denatured at 95'C for 5 min. The samples (10,u1 final volume) were then transferred on ice. Labeling reactions were done with 2 1tl of labeling mix (1 .5 p.M dGTP, dCTP, dTTP), 111 of O.1M DTT, 0.6 ltl of DMSO, 1 itl of cx-["S]dATP, and 2 ltl (2-3 U) of Sequenase. Termination reactions were according to manufacturer's instructions . The sequencing reactions were then analyzed by standard electrophoresis and autoradiography.
Results
A Large Fraction ofRn'pheral Blood .y/b Cells Recognize Molt-4 Lymphoma Cells. We generated a large panel of y/b T cell clones (78) from peripheral blood by using PHA as a polyclonal stimulator and tested the ability of these clones to lyse different tumor target cells. This random set of clones expressed many different sorts of specificities. A few were alloreactive, recognizing specific human class II alleles (as tested on various EBV cells), and a very small set specifically saw other antigens. For example, one clone recognizes all mouse T cells. In addition, as reported by other authors (25, 26) , we found that many of the y/b clones, when tested soon after in vitro restimulation, exert a non-MHC-restricted killing against a variety of tumor targets, including K562, U937, OVCA 432, Raji, Jurkat, and Molt-4 ( Fig. 1 A) . When the same clones were rested for 4-8 wk, they progressively lost this nonspecific reactivity, however, most of them retained the ability to lyse Molt-4 ( Fig. 1 B) .
To investigate whether the y/b receptor is involved in Molt-4 recognition, we performed antibody inhibition experiments with 61 and TiyA mAbs, which recognize Cband Vy9-encoded epitopes (1, 5) . Fig. 1 C shows that these mAbs completely abolished Molt-4 killing by five Vy9-positive clones. Similar results were obtained with all the Vy9+ clones tested . In some experiments, we also measured the release of serine esterases, which appears to be specific for the killing mediated by the TCR and not by a putative NK receptor (27) . Serine esterases activity was detected in the supernatant after triggering of Vy9/VS2 cells with Molt-4 (data not shown) . Thus, both mAb inhibition and serine esterases release indicate that TCR is involved in Molt-4 recognition .
In contrast to the anti-receptor antibodies, mAbs directed to various structures on the target were ineffective (Fig. 1  D) . Neither anti-MHC antibodies (W6/32, L243, B7 .21 mAbs), nor anti-(32-microglobulin antiserum, nor anti-CDla, -b, and -c mAbs were able to block Molt-4 killing. In addition, Molt-4 variants that express low levels of CD1a and CD1c were recognized and killed by rested clones (data not shown) . These results suggest that the TCRs of y/S cells recognize a Molt-4 surface structure that is neither a classical MHC molecule nor CD1 .
Recognition ofMolt-4 Is a Property of Cells Expressing the Vy9-Cyl Chain. To assess the relationship between the large set of cells recognizing Molt-4 and the set of cells expressing Vy9/VS2, we isolated a new panel of 189 random y/S clones from peripheral blood using PHA and tested them for the reactivity with the Vy9-specific antibody TiyA, and for their capacity to kill Molt-4 . None of the TiyA -clones tested (60/60) and all but one TiyA+ clones (128/129) killed Molt-4 . This finding indicates that the two characteristics define one set of cells . In peripheral blood, almost all Vy9+ cells recognize Molt-4, a specificity not shared by Vy9 -cells.
Since most peripheral Vy9+ cells also express VS2, we asked whether recognition of Molt-4 required both V genes.
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De Libero et al. We selected from our collection of y/S clones (4) those expressing "unusual" pairings of Vy and V8 chains, and measured their reactivity to Molt-4 . Table 1 shows 41 y/b clones, classified according to the expression of V-y9, V62, and the Cy1 vs. the Cy2 isotypes (i.e., the disulphide-or nondisulphide-linked constant region heterodimer) . Although the number of clones is small, and two out of the possible eight combinations are missing, the following conclusions can be made : (a) killing of Molt-4 requires both Vy9 and Cyl, but does not require VS2 ; and (b) expression of Vy9/Cyl, though necessary, is not sufficient since one Vy9+ clone (E13) kills K562 (data not shown) but does not kill Molt-4 . Thus, Molt-4, like the well-known superantigens, is recognized by nearly all cells expressing a single particular V gene, though in the case of 'r/6 cells, an additional requirement exists for the disulphide-linked form of the constant region .
Stimulation of PBMC with M. tuberculosis Leads to the Selective Expansion of Vy9/Va2 Cells. It has recently been reported that a large number of human y/6 cells proliferate in response to mycobacterial lysates (29) . To characterize the TCR of these cells, we stimulated PBMC with heat-killed MT. Cells from six different donors proliferated vigorously to MT. The proliferating cells were identified by FACS® as large cells with forward and side scatter parameters and analyzed with a panel of mAbs specific for human Vy or VS chains (Fig. 2 A) . In five of six donors, there was a striking increase of y/b cells, identified as b+ (with the mAb bl) and oi/f3 -(with BMA032), from 1-5% at day 0, to 40-90% at day 14 . The proliferating y/S cells also stained with anti-V62 (BB3) and antiVy9 (TiyA) mAbs, while they did not react with anti-V31 (8TCS1), nor with antiVy4 (4A11) mAbs, indicating 
The clones were derived from peripheral blood or postnatal thymus as specified in reference 4. The Vy and V6 genes are named according to references 4 and 28 except for V67, which is a new V gene, and V68, which has already been reported in a TCR tx chain (N. Migone, et al ., manuscript in preparation). Blanks are not done. that virtually all the y/S cells carried a Vy9/V62 receptor (data not shown) . PBMC from the same donors did not show a preferential expansion of y/6 cells when stimulated with PPD, tetanus toxin, or 30 U/ml of IL-2 (Fig . 2, B-D) . These results indicate that only stimulation with mycobacteria and not with PPD or other protein antigens specifically activates Vy9/VS2 cells in PBMC .
The proliferating T cells from MT cultures were expanded in IL2 and tested for their response to MT The cell lines proliferated in response to MT but not to PPD or tetanus toxoid (data not shown) . They also killed mycobacteria-pulsed APC (data not shown) . Thus, the response to MT is selectively comprised of y/S cells bearing Vy9/VS2 .
Recognition ofMolt-4 and M. tuberculosis Are Properties of Overlapping Sets of y1b T Cells. Since Vy9 is associated with recognition of Molt-4, the finding that Vy9/VS2 characterizes y/S cultures specific for MT led us to ascertain whether the two specificities are associated with separate or overlapping sets of T cells. We therefore generated a set of clones from cultures responding to MT and analyzed their TCR usage and their specificity to various antigens. Table 1 shows a comparison of these clones with a set of randomly derived clones from peripheral blood .
Every clone derived from MTspecific cell lines reacts with BB3 and TiyA mAbs and therefore expresses a Vy9/VS2 TCR (Table 1 B) . Furthermore, all the clones that were tested express the disulphide-linked V79-JP-Cy1/VS2J1 receptor, Table 2 . TCR-y Sequences
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Antigen Specificities of V-y9/VS2 Cells and lyse Molt-4 targets . The molecular analysis thus confirmed that the receptor of MT reactive clones is Vy9/VS2 . In the sample of randomly derived clones (Table 1 A), 11 of 23 of the Vy9+, and 11 of 14 of the Vy9/VS2-tested clones proliferated to MT-pulsed APC, whereas none of the clones bearing other TCR combinations showed any proliferative responses to this bacterium .
Thus, the clones specific for MT appear to comprise a major proportion of the set specific for Molt-4 . However, unlike the Molt-4 specificity, which appears to be dictated solely by the Vy9-Cy1 chain, reactivity to MT requires the additional component of VS2 .
Because -20% of Vy9/VS2 tested cells do not react with MT, we asked whether any particular N, D, or J segment correlated with this specificity by sequencing the junctional regions of Vy9/VS2 clones belonging both to MT-reactive and nonreactive groups . The results showed that the examined TCRs have different y (Table 2 ) and S (Table 3) functional sequences, with no obvious consensus amino acid sequences or lengths ( Table 4 ) that might distinguish between the two groups of cells . Two clones (1 .7, which does not respond to MT, and C .15, which does respond to this stimulation) have an identical Vy9 chain but different Vbs, suggesting that the y chain alone does not confer the specificity and also that the S chain is important . Thus, while Molt-4 behaves like a cellular superantigen, specificity for MT has features more closely resembling specificity to normal antigens. The characteristics summarized in Tables 2-4 
The V and J y and S segments used are specified in Tables 2 and 3. with, for example, the response to cytochrome c in mice, where T cell clones of one particular functional phenotype always express the identical Vcx and Vii combination, but vary at junctional regions (30) . Characteristics of the Response to M. tuberculosis. To analyze the biology of the response to MT, we began with the question of MHC restriction . We first asked whether the y /S clones showed any preference for antigen in the context of polymorphic MHC molecules using EBVB cells bearing different HLA haplotypes as APC. Fig . 3 shows that all tested EBVB cells, irrespective of MHC type, functioned as APC for MTreactive y/b clones, suggesting that polymorphic MHC determinants are not involved in the stimulation of they/b clones . We also attempted to identify any nonpolymorphic restriction molecules by mAb inhibition using mAbs specific for framework regions of class I molecules (W6/32), as well as anti-a2-microglobulin antisera, anti-DR, and anti-DP mAbs. Although these antibodies consistently block antigen recognition by TCR-ci/a+ cells (data not shown), we failed to detect consistent inhibition of y/b cell proliferative responses or lysis of mycobacteria-pulsed target cells (data not shown) .
Having found no special role for APC of any particular haplotype, we asked whether APC are needed at all . Fig . 4 shows that T cells give a low response to MT alone, while they proliferate well when both EBVB cells and antigen are present . These findings indicate that APC are indeed required for maximum stimulation of y/b cells, although selfpresentation by the T cells themselves may occur. Both PBMC (data not shown) and EBVB cells functioned as APC, while a T cell line Gurkat) did not . Thus, the bacterial antigens, like conventional antigens presented to CD4 or CD8 T cells, require the presence of APC for optimal activation of y/b T cells. Whether this is due to a more efficient processing, or presentation by APC, is under investigation.
To study the antigen specificity of y/b clones, we used APC pulsed with different bacteria such as MT, L. monocytogenes, or E. coli . Interestingly, (Table 5) nize APC pulsed with different bacteria, suggesting that bacteria-pulsed APC display common structures.
Discussion
Our results indicate that a large fraction of human peripheral blood y/b cells is able to recognize Molt-4 as well as bacteria-pulsed APC . While these two "superspecificities" are both found within the Vy9/VS2 population, which is the most abundant y/b subset in peripheral blood, the two sets are not precisely overlapping and can be defined as follows.
The major set of peripheral y/b T cells, those that recognize Molt-4, is comprised ofclones bearing a disulphide-linked Vy9-bearing receptor. The VS chain seems to be less critical, since at least two different Vbs can pair with Vy9-Cy1 chains in Molt-4-reactive clones. Thus, the recognition of Molt-4 by human Vy9+ cells resembles the recognition of Mls ligands by mouse T cells expressing particular V,3 gene products (13) . In both cases, the structure of the second TCR chain and of N, D, or J regions seems to be largely irrelevant .
The molecular nature of the Molt-4 associated and Mls gene-controlled superantigens remains to be elucidated . Recently, Vy9-related ligands have also been found to be expressed by Daudi cells (31) and by staphylococcal enterotoxin A (SEA) (32) . It is possible that cellular superantigens identical or related to the Molt-4 and Daudi superantigens, or microbial superantigens like SEA, might play a role in the expansion of a subset of Vy9+ cells in the periphery. However, this mechanism cannot explain the preferential use of V62 by the vast majority of circulating Vy9+ cells . The second superspecificity, directed against mycobacteriapulsed APC, is found in 80% of peripheral blood Vy9/V62 cells. This reactivity is dependent on the expression of Vy9 and V62, though the expression of both these gene segments is not completely sufficient, since -20% of Vy9+/V62+-tested clones do not recognize mycobacteria-pulsed APC. It is not yet clear whether the lack of reactivity is due to the presence of inappropriate TCR junctional regions or to other reasons .
The Vy9/V62 TCR of the mycobacteria-reactive cells exhibit extensive junctional diversity. In the context of the model proposed by Davis and Bjorkman (7), we might interpret our data to indicate that the mycobacteria-reactive y/6 TCRs contact a monomorphic restriction molecule with Vy9-and V62-encoded regions and an antigenic determinant using regions encoded by the junctional sequences. However, we found no evidence that any known MHC class II, nor any known or unknown 02-microglobulin-associated class I, molecule acted as restriction elements for either of the two major specificities .
In spite of the lack of MHC restriction, we found that APC were required for optimal proliferation of ylb cells . We also found that some y/6 clones, originally raised with MT, also recognize APC pulsed with different bacteria, such as L. monocytogenes and E. coli .
References
These findings indicate that APC play an active role in antigen presentation but do not establish the origin of the stimulating ligand . There are two possibilities. First, this ligand may be derived from the bacteria themselves. Several reports have shown that some y/6 cells recognize heat shock proteins (HSPs) (33) (34) (35) , and different bacteria express related HSPs that may provide crossreactive epitopes (36) . A recent analysis of a set of mouse ylb T cell hybridomas that respond to PPD and that recognize a HSP-derived peptide (35, 37) shows that these cells, like the clones described here, display considerable junctional diversity and lack classical MHC restriction (37, 38) .
The second possibility is that pulsing with bacteria might induce the appearance of new surface proteins from the APC themselves . It is known, for example, that LPS can induce the expression of the MT9-defective mammary tumor virus genome in normal B cells (39) . If this is the case with the ligand recognized by Vy9/Vb2 cells, then the APC would display a comparable set of ligands irrespective of the bacteria used .
An apparent paradox is the finding that Vy9/V62 cells are a minor population of y/6 cells in tissues (40-43, G. De Libero unpublished results), where immune responses and cell proliferation occur (44) , while they represent a major subset in peripheral blood. Vy9/Vb2 cells might localize in tissues during inflammatory responses (45), become activated, and then recirculate in the blood. Studies on the recirculation patterns of y/b cells in sheep show that they do not circulate through the T or B cell areas of lymph nodes, suggesting that they may have nothing to do with normal T-B responses (46) . Studies on the recirculation and activation patterns of these cells in patients with different diseases may help to clarify their function .
